Latest Strategic Partnership News

OD6 Metals has raised $2.5 million through a strongly supported placement to fast-track rare earth testwork and copper drilling programs at its flagship Australian projects.

AdAlta Limited outlines its innovative 'East to West' cellular immunotherapy approach, in-licensing Asian CAR-T assets and progressing clinical trials in Australia to unlock value. The company also seeks partners for its anti-fibrotic and anti-malarial protein therapeutics.

iTech Minerals has identified two extensive high-grade antimony zones at its Reynolds Range project in the Northern Territory, revealing significant mineralisation previously overlooked. The company plans to commence drilling later this year to explore these promising targets further.

Opthea has successfully settled its Development Funding Agreement, avoiding a potential $680 million liability and securing $20 million in cash. Leadership changes include the CEO and CFO stepping down, with the Chairman assuming CEO duties.

HUB24 Limited reported robust FY25 results, driven by a 34% surge in platform funds under administration and a 44% rise in underlying net profit after tax. The company expanded its adviser base and boosted dividends, reinforcing its leadership in Australia's wealth management technology sector.

Amplitude Energy has delivered record production and earnings in FY25, driven by operational improvements and a strategic joint venture for the East Coast Supply Project.

Amplitude Energy Limited reported a 22% revenue increase to A$268.1 million for FY25, narrowing its net loss significantly while progressing its East Coast Supply Project with a new joint venture partner.

Challenger has reported a robust FY25 performance, with normalised net profit after tax rising 9% to $456 million and return on equity exceeding targets. The company’s strategic focus on annuities and digital transformation positions it well for continued growth in FY26.

Challenger Limited reported a 9% increase in normalised net profit after tax for FY25, driven by strong Life business cash earnings and resilient Funds Management performance despite net outflows. The company also announced an 11% dividend increase and provided positive FY26 EPS guidance amid ongoing regulatory reforms.

Challenger Limited reported a robust FY25 with a 9% rise in normalised profit and a strategic push into digital transformation and retirement income solutions.

Challenger Limited celebrates four decades with a robust 9% rise in net profit and a strategic digital transformation, positioning itself at the forefront of Australia’s retirement income market.

Rhythm Biosciences has launched a $3.75 million placement alongside an offer of over 52 million new options, all contingent on shareholder approval. The move aims to bolster working capital as the company advances its cancer diagnostic products.